{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head&page=8", "query": { "condition": "Head", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 4250, "total_pages": 425, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T16:03:18.332Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05249426", "title": "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC)" ], "interventions": [ { "name": "BI 765063", "type": "DRUG" }, { "name": "Ezabenlimab", "type": "DRUG" }, { "name": "BI 836880", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Investigator´s Choice Chemotherapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-04-12", "completion_date": "2026-06-22", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05249426" }, { "nct_id": "NCT04465487", "title": "Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "REGN6569", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2020-10-05", "completion_date": "2025-02-07", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 4, "location_summary": "Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04465487" }, { "nct_id": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cervical Neoplasms", "Endometrial Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Gallbladder Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms", "Triple Negative Breast Neoplasms", "Hepatocellular Carcinoma", "Urinary Bladder Neoplasms", "Ovarian Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab Co-Formulation", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 611, "start_date": "2021-09-16", "completion_date": "2025-08-05", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 14, "location_summary": "Anchorage, Alaska • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05007106" }, { "nct_id": "NCT03382158", "title": "International PPB/DICER1 Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pleuropulmonary Blastoma", "Sertoli-Leydig Cell Tumor", "DICER1 Syndrome", "Cystic Nephroma", "Wilms Tumor", "Pineoblastoma", "Renal Sarcoma", "Nodular Hyperplasia of Thyroid", "Nasal Chondromesenchymal Hamartoma", "Ciliary Body Medulloepithelioma", "Neuroblastoma", "Pituitary Cancer", "Embryonal Rhabdomyosarcoma", "Ovarian Sarcoma", "Gynandroblastoma", "Thyroid Carcinoma", "Embryonal Rhabdomyosarcoma of Vagina (Diagnosis)", "Embryonal Rhabdomyosarcoma of Uterus (Diagnosis)", "Embryonal Rhabdomyosarcoma of Cervix" ], "interventions": [], "intervention_types": [], "sponsor": "Children's Hospitals and Clinics of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Minutes", "maximum_age": "100 Years", "sex": "ALL", "summary": "0 Minutes to 100 Years" }, "enrollment_count": 3400, "start_date": "2016-12-06", "completion_date": "2035-12-06", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03382158" }, { "nct_id": "NCT05706558", "title": "Retrospective Review of Esophageal Cancer at MSKCC", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "Esophagectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4000, "start_date": "2016-12-13", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05706558" }, { "nct_id": "NCT05326555", "title": "Dynamic Vision Testing and Concussion Management Dream Team 65", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head Injury", "Sport Injury", "Concussion, Brain" ], "interventions": [ { "name": "Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "California State University, Northridge", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2021-10-01", "completion_date": "2024-10-01", "has_results": false, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 1, "location_summary": "Northridge, California", "locations": [ { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05326555" }, { "nct_id": "NCT04408898", "title": "SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "ADP-A2M4 in combination with pembrolizumab.", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Adaptimmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2020-07-02", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-11-16", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 8, "location_summary": "Phoenix, Arizona • San Diego, California • Kansas City, Kansas + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04408898" }, { "nct_id": "NCT01044433", "title": "Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2009-10", "completion_date": "2017-03-03", "has_results": true, "last_update_posted_date": "2020-03-19", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01044433" }, { "nct_id": "NCT02422979", "title": "Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2", "type": "COMBINATION_PRODUCT" }, { "name": "PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Rakuten Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-06", "completion_date": "2019-02-25", "has_results": false, "last_update_posted_date": "2020-02-26", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Chicago, Illinois + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02422979" }, { "nct_id": "NCT02994069", "title": "Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell", "Head and Neck Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "XRT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Susanne Arnold", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-11", "completion_date": "2029-10-31", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-18T16:03:18.332Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02994069" } ] }